Sarepta Provides Update for SRP-9001-303: ENVISION study enrollment in U.S.

June 8, 2023

On June 8, 2023, Sarepta Therapeutics shared important enrollment updates about their ENVISION study (SRP-9001-303).

Please read their Community Letter by clicking here.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open